Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

British Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2008, Pages 629-639

  Feng, Yan ^a   Pollock, Bruce G ^b,c   Coley, Kim ^d   Marder, Stephen ^e   Miller, Del ^f   Kirshner, Margaret ^c   Aravagiri, Manickam ^e   Schneider, Lon ^g   Bies, Robert R ^b,c,d  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CATIE trial; CYP2D6; NONMEM; Pharmacokinetics; Risperidone

Indexed keywords

CLOZAPINE; FLUPHENAZINE DECANOATE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 55149091794     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03276.x     Document Type: Article

References (33)

1. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001 153 : 238 43.
2. Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry 1993 38 (Suppl. 3 S89 95.
3. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988 247 : 661 70.
4. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005 19 : 395 401.
5. Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995 122 : 223 9.
6. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999 359 : 147 51.
7. He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 1995 10 : 19 30.
8. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002 22 : 419 23.
9. Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) 2006 183 : 490 9.
10. Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005 25 : 527 32.
11. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005 66 : 15 27.
12. Vermeulen A, Piotrovsky V, Ludwig E. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn 2007 34 : 183 206.
13. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991 32 : 669 70.
14. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003 29 : 33 43.
15. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003 29 : 15 31.
16. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Leiberman JA Catie-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006 355 : 1525 38.
17. Aravagiri M, Marder SR, Van Putten T, Midha KK. Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. J Pharm Sci 1993 82 : 447 9.
18. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977 5 : 445 79.
19. Beal B, Sheiner L. (1989-1998) NONMEM User's Guide, Part I. University of California San Francisco, San Francisco, CA, 1992.
20. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995 12 : 1845 55.
21. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001 28 : 231 52.
22. Akaike H. A new look at the statistical model indentification. IEEE Trans Automat Control 1974 AC-19 : 716 23.
23. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003 56 : 96 103.
24. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000 68 : 130 42.
25. Kang D, Verotta D, Krecic-Shepard M-E, Modi NB, Gupta SK, Schwartz JB. Population analysis of sustained-release verapamil in patients: effects of sex, race and smoking. Clin Pharmacol Ther 2003 73 : 31 40.
26. Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 2004 44 : 1352 9.
27. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993 21 : 1134 41.
28. Schneider L, Dagerman K, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005 294 : 1934 43.
29. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at http://www.cypalleles.ki.se (last updated: 21 May 2008).
30. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990 265 : 17209 14.
31. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002 3 : 229 43.
32. Feng Y, Pollock BG, Ferrell RE, Kimak MA, Reynolds CF III., Bies RR. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006 61 : 558 69.
33. Feng Y, Pollock B, Reynolds C, Bies R. Paroxetine pharmacokinetics in geriatric patients. AAPS PharmSci 2004 6 (S1). Abstract M1116. Available at http://www.aapsj.org/abstracts/AM_2004/AAPS2004-003172.pdf (last accessed: 5 August 2008).